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Huntington’s disease (HD) is an autosomal dominant neurological disorder caused by a CAG repeat expansion in huntingtin
gene. Mutated huntingtin (mHtt) is thermodynamically unfavorable misfolded what promotes the formation of inclusion
bodies. Intermediary steps of mHtt aggregation evoke a progressive damage in striatum, cortex and hippocampus, what
result in movement, cognitive and psychiatric disorders. There are basically three mechanisms of HD progression:
trancrisptional dysregulation, impairment of axonal transport and mitochondria dysfunction.
Molecular basis of Huntington’s disease (1)
Inhibition of protein aggregation (1)RNA interference and antisense nucleotides (2)
Cell-based therapies + RNA interferences and antisense
nucleotides (3)
References
(1) Aronin, D. W. (2011;). Oligonucleotide therapeutic approachesfor Huntington disease. J Clin Invest.121(2),:500–507 .
(2) Kim, S. K.-T. (2014). Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington’s Disease. Exp. Neurobiol. 23 (1):36-44.
(3) Yiju Chen, R. L. (2014 ). Cell-based therapies for Huntington’s therapies. Drug discovery today, 
http://dx.doi.org/10.1016/j.drudis.2014.02.012.
RNA interference and antisensenucleotides block the expression of
huntingtin by impairing its translation.
Inhibition of protein aggregation can be achieved by chaperone
inducible drugs, anti-aggregation drugs and inhibitors which impair
chaperones activity.
Cell-based therapies is focused on replenish lost neuronal population
with induce-pluripotent stem cells (iPS cells) or embryonic stem cells
(ES cells). This treatment would be specially suitable in advances stages
of the disease.
Conclusions
Combining different therapies to stop the progression of the disease
but also to reverse to the healthy situation may be the best option, e.g:
cell-based therapies + RNA interference and antisense nucleotides.
Nowadays, only palliative cures exist, therefore many treatments
focused on several points of molecular progression of this disease
are being developed. The aim of this study was to describe the
pathogenic mechanisms involved in HD and novel therapeutic
avenues to treat this disorder.
